PT Medikaloka Hermina (HEAL) Q3 2026 earnings summary

Executive summary

• 3Q26 delivered record quarterly revenue of IDR1.914tn and EBITDA of IDR530bn; PATMI reached IDR110bn, up 19.6% QoQ and 16.6% YoY.

• 9M26 revenue rose to Rp5,522,992 million from Rp5,287,968 million, while operating income and net income declined to Rp689,549 million and Rp390,332 million, respectively.

Financial highlights

• 3Q26 revenue grew 4.8% QoQ and 0.8% YoY; EBITDA increased 10.6% QoQ and 1.9% YoY, with a 28% EBITDA margin.

• 9M26 gross profit was Rp1,896,502 million versus Rp1,850,362 million; cost of revenue rose to Rp3,626,490 million from Rp3,437,606 million.

• 9M26 operating expenses increased to Rp1,227,093 million from Rp1,117,880 million; operating income declined to Rp689,549 million from Rp751,104 million.

• 9M26 net income was Rp390,332 million versus Rp451,066 million; net income attributable to parent owners fell to Rp303,318 million from Rp356,017 million, and EPS to Rp19.84 from Rp23.67.

Outlook and guidance

• Bed capacity rose 8.2% to 9,122 by 3Q26; 9M26 inpatient admissions increased 3.2% YoY to 550,000, while bed occupancy was 67.9%, down 3.7 percentage points YoY.

• Hospital construction in progress was expected to be completed in 2026; projects included multiple hospital builds and expansions with reported completion estimates ranging from 20% to 95%.